erlotinib hydrochloride has been researched along with dinoprostone in 7 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 29,105 | 1,346 | 6,357 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | dinoprostone (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
| Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Aoki, N; Celis, E; Harabuchi, Y; Kimura, S; Kobayashi, H; Kumai, T; Oikawa, K | 1 |
| Cristea, MC; Dowell, JE; Dubinett, SM; Elashoff, RM; Figlin, RA; Fishbein, MC; Gardner, BK; Koczywas, M; Milne, GL; Reckamp, KL; Wang, HJ | 1 |
| Donnini, S; Finetti, F; Giachetti, A; Hanaka, H; Radmark, O; Santi, R; Terzuoli, E; Villari, D; Ziche, M | 1 |
| López-Contreras, F; López-Muñoz, R; Martin-Martin, A; Molina-Berríos, A; Muñoz-Uribe, M; Pérez-Laines, J; Rivera-Dictter, A | 1 |
1 trial(s) available for erlotinib hydrochloride and dinoprostone
| Article | Year |
|---|---|
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Dinoprostone; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models | 2015 |
6 other study(ies) available for erlotinib hydrochloride and dinoprostone
| Article | Year |
|---|---|
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Tumor-derived TGF-β and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor.
Topics: Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Transforming Growth Factor beta | 2014 |
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Survival; Dinoprostone; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Human Umbilical Vein Endothelial Cells; Humans; Integrin alpha6; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice, Nude; Prostaglandin-E Synthases; Prostatic Neoplasms | 2015 |
Reconsidering the Role of Cyclooxygenase Inhibition in the Chemotherapeutic Value of NO-Releasing Aspirins for Lung Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Dinoprostone; Drug Synergism; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Nitric Oxide; Nitro Compounds | 2019 |